



HAL
open science

Acute megakaryoblastic leukemia AML FAB-M7 in a patient 15 years after kidney transplantation

Alexandra Scholze, Igor W. Blau, Martin Tepel

► **To cite this version:**

Alexandra Scholze, Igor W. Blau, Martin Tepel. Acute megakaryoblastic leukemia AML FAB-M7 in a patient 15 years after kidney transplantation. *Annals of Hematology*, 2010, 90 (7), pp.843-844. 10.1007/s00277-010-1084-0 . hal-00615404

HAL Id: hal-00615404

<https://hal.science/hal-00615404>

Submitted on 19 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Editorial Manager(tm) for Annals of Hematology
Manuscript Draft

Manuscript Number: AOHE-D-10-00398R1

Title: Acute megakaryoblastic leukaemia AML FAB-M7 in a patient 15 years after kidney transplantation

Article Type: Letter to the Editor

Keywords: Kidney transplantation, leukaemia, AML FAB-M7, fever of unknown origin

Corresponding Author: Dr Martin Tepel,

Corresponding Author's Institution:

First Author: Alexandra Scholze

Order of Authors: Alexandra Scholze; Igor W Blau; Martin Tepel

Abstract: Letter to the Editor

Acute megakaryoblastic leukaemia AML FAB-M7 in a patient 15 years after kidney transplantation

Response to Reviewers: Arnold Ganser, M.D.
Editor-in-Chief
Annals of Hematology

Dear Editor

please find enclosed the revised version of our manuscript AOHE-D-10-00398

"Acute megakaryoblastic leukaemia AML FAB-M7 in a patient 15 years after kidney transplantation "

by Alexandra Scholze, Igor W. Blau, Martin Tepel

for publication in Annals of Hematology as a Letter to the Editor.

The Answers to the Reviewer's comments are given below.

"All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language, except as an abstract."

Enclosed you find the manuscript, uploaded online, including all figures.

Competing interests statement: The authors declare that they have no competing financial interests.

Yours sincerely

Dr. Martin Tepel, M.D.
Odense University Hospital and University of Southern Denmark
Institute for Molecular Medicine / Cardiovascular and Renal Research
Winsløwparken 21.3
DK-5000 Odense C
Denmark
Phone: +45-6550-3755
Fax. +45-6613-3479
Email. mtepel@health.sdu.dk

Answers to Reviewer's comments

1. Molecular changes were not determined.
2. Because the patient presented severely disabled (Karnofsky score 30), the therapy was limited.
3. The immunosuppressive regimen consisted of cyclosporine A and prednisolone. The antihypertensive treatment comprised furosemide, a beta blocker and an ACE inhibitor. No episodes of acute rejection had occurred in the post-transplant course.
4. The typographical errors were corrected

***Conflict of interest**

[Click here to download Conflict of interest: Ann Hematol Conflict of interest.pdf](#)

Letter to the Editor

Acute megakaryoblastic leukaemia AML FAB-M7 in a patient 15 years after kidney transplantation

Alexandra Scholze¹, Igor W. Blau², Martin Tepel¹

¹Odense University Hospital, Department of Nephrology, Odense, Denmark,

²Charité Campus Benjamin Franklin, Department of Hematology, Oncology and Transfusion Medicine, Berlin, Germany.

Word count 594 words

Address for correspondence:

Dr. Martin Tepel

Odense University Hospital, Department of Nephrology

University of Southern Denmark, Institute of Molecular Medicine

Winslowparken 21.3

DK 5000 Odense C

Denmark

Fax. +45-6613-3479

Email. mtepel@health.sdu.dk

Dear Editor

1
2
3 we report a case of acute megakaryoblastic leukaemia French-American-British classification
4 M7 (AML FAB-M7), a rare form of leukaemia in the late post-transplantation period, which
5 occurred in a patient 15 years after kidney transplantation. A 42-year-old man presented
6 severely disabled (Karnofsky score 30) with fever of unknown origin and pancytopenia. He
7 complained of weakness, loss of appetite and elevated temperature for several days, ranging
8 from 38°C to 40°C. The patient had been transplanted with a cadaveric kidney 15 years
9 earlier. The cause of end stage renal disease was unknown. No episodes of acute rejection had
10 occurred in the post-transplant period. There was a slow progressive loss of renal function, a
11 renal transplant biopsy obtained 1 year earlier showed a pronounced chronic allograft
12 nephropathy with a severe arteriolo-hyalinosis but no signs of acute rejection or calcineurin
13 inhibitor toxicity. The immunosuppressive regimen consisted of prednisolone (10 mg/day)
14 and cyclosporine A (200 mg/day) throughout. The antihypertensive treatment comprised
15 furosemide, beta blockers and angiotensin converting enzyme inhibitor. White blood count
16 was reduced to 1.83/nL consisting of 76% neutrophilic granulocytes, 11% lymphocytes 13 %
17 monocytes 0% eosinophilic granulocytes and 0% basophilic granulocytes. Platelet count was
18 reduced to 70/nL and hemoglobin was reduced to 7.0g/dL. The clinical evaluation of the skin,
19 head and neck, heart and lung, abdomen including the side of transplantation, and the
20 neurological status showed no pathological findings. Kidney function was stable with
21 creatinine values of 400µmol/L. Urinalysis did not show urinary tract infection. Blood
22 cultures were negative. Ultrasound of the transplanted kidney showed no pathologic findings.
23 A computed tomography of thorax and abdomen did not show pathological findings except
24 enlargement of the spleen with 15 cm. Lymph node enlargement was not observed.
25 Transoesophageal echocardiography did not show signs of endocarditis. A broncho-alveolar
26 lavage excluded pneumocystis carinii, mycobacteria or legionellae, and the patient was tested
27 negative for human immunodeficiency virus and hepatitis. Screening for cytomegalovirus was
28 negative, whereas polymerase chain reaction for Epstein-Barr virus was slightly positive. A
29 bone marrow aspirate showed mainly myeloid cells with enhanced expression of cluster of
30 differentiation 13 (CD 13), representing an early granulocytic antigen. On the other hand,
31 CD 33, an antigen of myeloid progenitor cells, was observed in only 3%. The stemcell factor
32 receptor c-kit, a marker of immature blast cells, was enhanced and could be detected in 4% of
33 cells. A cytogenetic analysis showed no structural or clonal numerical chromosomal
34 aberrations. The cytological picture showed an extensive megakaryopoiesis with a shift to
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

early cell stages and partially atypical nuclei (**Figure 1**). Staining showed an excess of stored iron. The erythropoiesis/granulopoiesis (E/G) ratio was markedly shifted in favor of granulopoiesis. All specimens showed a population of megakaryocytic blast cells. Cytology of the bone marrow aspirate showed acute AML FAB-M7. **Because the patient was severely disabled, a therapy with low dose cytarabine was started.** However, the patient developed severe aplasia and septicemia. The patient died 3 weeks after diagnosis.

A wide variety of causes are considered when fever occurs in a patient after renal transplantation. The most common causes are viral, bacterial or opportunistic infections, transplant rejection, side effects of new medications or malignancies [1]. It appears that AML does develop more frequently after transplantation than in the normal population [2-4]. The incidence of AML after solid organ transplantations is about 0.2 to 2.5%. Post-transplant-AML seems to develop after a median interval of 5 years (range 1-17 years). It is heterogeneous with respect to FAB classification and may show chromosomal and molecular changes [4]. However, the present case shows that AML FAB-M7 may develop as treatment related without carrying multiple chromosomal aberrations.


References

1. Cohen D, Galbraith C (2003) General health management and long-term care of the renal transplant recipient. *Am J Kidney Dis* 38(Suppl 6): S10-24
2. Gorschlüter M, Glasmacher A, Risse F, Klein B, Klehr HU, Mezger J (1997) Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient. *Nephrol Dial Transplant* 12: 593-595
3. Subar M, Gucalp R, Benstein J, Williams G, Wiernik PH (1996) Acute leukaemia following renal transplantation. *Med Oncol* 13: 9-13
4. Thalhammer-Scherrer R, Wieselthaler G, Knoebl P, Schwarzinger I, Simonitsch I, Mitterbauer G, Berlakovich GA, Mannhalter C, Haas OA, Mayer G, Muehlbacher F, Wolner E, Klepetko W, Lechner K, Jaeger U (1999) Post-transplant acute myeloid leukemia (PT-AML). *Leukemia* 13: 321-326

Figure legend

Figure 1. Bone marrow aspirate in a patient with recurrent fever of unknown origin and pancytopenia 15 years after renal transplantation. Cells of the hematopoiesis are shown. Arrows indicate megakaryoblasts, i.e. large cells with basophilic cytoplasm and loose chromatin in their eccentric and noncircular nucleus. Cytological picture of the cellrich, leukaemic bone marrow led to the final diagnosis of acute megakaryoblastic leukaemia French-American-British M7 (AML FAB-M7).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



Scholze et al., Figure 1.